DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rebif (Interferon Beta-1a) - Summary



REBIF (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons.

REBIF (interferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability.

See all Rebif indications & dosage >>


Media Articles Related to Rebif (Interferon Beta-1A)

Multiple sclerosis: Results from ZINBRYTA Phase 3 DECIDE study highlighting efficacy compared to Interferon Beta-1a published
Source: Multiple Sclerosis News From Medical News Today [2015.10.09]
Full results from the Phase 3 DECIDE study published this week in the New England Journal of Medicine (NEJM), as well as new post-hoc analyses of Phase 3 clinical data presented at an international...

more news >>

Published Studies Related to Rebif (Interferon Beta-1A)

Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. [2014]
function in MS... CONCLUSIONS: Different types of DMTs may improve some aspects of cognitive

Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories. [2013]
The appearance of neutralizing antibodies (NAbs) has significant clinical and regulatory consequences for interferons in patients with multiple sclerosis (MS). In a double blind, randomized clinical trial, 84 patients with relapsing remitting MS were enrolled in a 24month study period... As similar results were obtained from CinnoVex or Avonex in our study, we suggest that both medications will have a similar immunogenetic profile.

Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial. [2012]
USA) and CinnoVex (CinnaGen, Iran)... CONCLUSION: CinnoVex can be used as a safe and effective alternative to Avonex in

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. [2012]
combined with low-dose azathioprine and prednisone in multiple sclerosis... CONCLUSION: The tested combined therapeutic regimen does not improve long-term

Interferon beta for secondary progressive multiple sclerosis. [2012]
CONCLUSIONS: Well designed RCTs, evaluating a high number of patients

more studies >>

Clinical Trials Related to Rebif (Interferon Beta-1A)

Supplementation of VigantOL� Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif� Treatment [Completed]

The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone

supplement (cholecalciferol). Low levels of Vitamin D have been described to be associated with a higher risk of developing Multiple Sclerosis (MS), and it is known that up to 90% of patients with Multiple Sclerosis have Vitamin D deficiency. Rebif® is known to be an effective treatment for slowing down the progression of MS. The purpose of this research trial is to evaluate if VigantOL® oil on top of Rebif® has any benefit on the progression of MS compared to Rebif® and placebo. Disease activity will be assessed by clinical examination and Magnetic Resonance Imaging (MRI). The planned study treatment duration for each study participant is 48 weeks, and the study consists of a total of 8 visits. Study participants who are already passed Week 48 at the time of approval of Protocol Amendment 5 will have a study duration of 96 weeks and a total of 12 visits. During the study, the participant will undergo physical examination, neurological assessments, safety assessments, blood tests and urinalysis (including pregnancy tests).

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif� New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. [Completed]
This observational multicentric study is planned to assess the tolerability of Rebif New Formulation in an Australian clinical setting by the incidence of injection site reactions (ISRs). The study will allow the comparison of tolerability data with historical data for both Rebif New and classic formulations, and will do so by using the same pre- specified preferred terms of treatment emergent adverse events as done in historical studies. In addition, the study will analyse whether interaction(s) with a nurse impacts tolerability and the impact of Rebif New Formulation on the patient's Quality of Life.

An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis [Completed]
The aim of this case series was to document the effectiveness and compatibility of Rebif 44 or 22 g in the therapy of the chronic multiple sclerosis (MS) under practical conditions on a large collection of subjects. In addition, the side effects possibly occurring in the initial phase of therapy and satisfaction of the subject as well as the treating doctor was also documented.

Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif [Completed]
The study is planned to evaluate the cognitive functions in subjects with RRMS treated with interferon beta-1a, and its relationship to the fatigue and neurological dysfunction status.

Retrospective Cohort Study of Rebif Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) [Completed]
The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif (subcutaneous interferon [IFN]-beta-1a) in children and adolescents, using information already recorded in medical records. The study duration is 13 July 2010 (first data collected) to 13 July 2011 (last data collected). In this study, Data of the subjects evaluated between 1997 and 2009 was observed.

more trials >>

Reports of Suspected Rebif (Interferon Beta-1A) Side Effects

Injection Site Erythema (716)Multiple Sclerosis Relapse (680)Injection Site Pain (519)Influenza Like Illness (489)Fall (424)Fatigue (364)Headache (363)Injection Site Haematoma (335)Pain (268)Depression (265)more >>


Based on a total of 1 ratings/reviews, Rebif has an overall score of 6. The effectiveness score is 8 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.

Rebif review by 29 year old female patient

Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Moderate Side Effects
Treatment Info
Condition / reason:   Multiple Sclerosis
Dosage & duration:   250 mg taken 3x weekly for the period of 18 months
Other conditions:   none
Other drugs taken:   none
Reported Results
Benefits:   Reduce number of MS relapses
Side effects:   Flu like symptoms- aches, fever
Comments:   subcutaneous injection 3x weekly

See all Rebif reviews / ratings >>

Page last updated: 2015-10-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015